Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Atea Pharmaceuticals (Nasdaq: AVIR) reported Q4 and full-year 2025 results and a business update. The company completed enrollment in C-BEYOND (>880 patients) and expects C-BEYOND topline results mid-2026 and C-FORWARD results around year-end 2026 for the bemnifosbuvir/ruzasvir HCV regimen.Cash and investments were $301.8M at 12/31/2025; AT-587 for hepatitis E is expected to enter clinical development mid-2026.

#AVIR Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/AVIR/atea-pharmaceu...

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-2026 with Topline Results Anticipated Year-End 2026

#AVIR Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

www.stocktitan.net/news/AVIR/atea-pharmaceu...

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026 New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against HCV New Data Presented at The Liver Meeting ® , the Annual Meeting of AASLD,

#AVIR Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/AVIR/atea-pharmaceu...

‹ familiar ›

#arkart #oc #personal #avir #descentintoavernus #dungeonsanddragons #dnd

‹ lost boy ›

#arkart #oc #personal #avir #descentintoavernus #dungeonsanddragons #dnd

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America Atea Pharmaceuticals (Nasdaq: AVIR) has announced the dosing of its first patient in the global Phase 3 C-FORWARD trial outside North America for its HCV treatment program. The trial evaluates the combination of bemnifosbuvir and ruzasvir against sofosbuvir and velpatasvir for hepatitis C virus treatment.The treatment regimen is administered once-daily for 8 weeks in patients without cirrhosis or 12 weeks in patients with compensated cirrhosis. This marks the second Phase 3 trial in Atea's global program, following C-BEYOND which began enrolling patients in the US and Canada in April 2025.The company aims to develop a best-in-class HCV regimen with potential advantages including shorter treatment duration, low risk for drug-drug interactions, and no food effect requirements. HCV remains a significant health burden, affecting approximately 50 million people globally, including up to 4 million in the US.

#AVIR Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

www.stocktitan.net/news/AVIR/atea-pharmaceu...

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Atea Pharmaceuticals (NASDAQ: AVIR) reported Q1 2025 financial results and progress in its HCV drug development program. The company's Phase 3 C-BEYOND trial for its combination regimen of bemnifosbuvir and ruzasvir is actively enrolling patients in the US and Canada, with a second Phase 3 trial (C-FORWARD) set to begin mid-2025. Phase 2 results showed 98% efficacy in treatment-adherent patients with an 8-week regimen. The company ended Q1 2025 with $425.4 million in cash, down from $454.7 million in Q4 2024. Q1 net loss was $34.3 million ($0.40 per share), improved from a $63.2 million loss year-over-year. Atea reduced its workforce by 25% in Q1 2025, expecting $15 million in cost savings through 2027. The company is exploring strategic alternatives with Evercore and authorized a $25 million share repurchase program.

#AVIR Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/AVIR/atea-pharmaceu...

Breakthrough: Atea's New 8-Week Hepatitis C Treatment Enters Final Trial Stage Atea advances potential game-changing HCV therapy with shorter treatment duration. Phase 3 trial begins for 50M patient global market. Full analysis inside.

#AVIR Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

www.stocktitan.net/news/AVIR/atea-pharmaceu...

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement: The Atea

#AVIR Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

www.stocktitan.net/news/AVIR/atea-pharmaceu...

Major Shake-up Looms: Activist Investor Challenges Atea Pharmaceuticals Board Control Activist investor Bradley Radoff moves to reshape Atea Pharmaceuticals' leadership with three board nominations for 2025. Key governance battle unfolds at clinical-stage biotech. Full details inside.

#AVIR Atea Pharmaceuticals Issues Statement Regarding Director Nominations

www.stocktitan.net/news/AVIR/atea-pharmaceu...

Major Breakthrough: Atea's New Hepatitis C Drug Enters Final Testing with Shorter Treatment Time Atea launches global Phase 3 trials for bemnifosbuvir in HCV treatment, featuring potential 8-week regimen versus standard 12-week therapy. 1,600 patients targeted worldwide.

#AVIR Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

www.stocktitan.net/news/AVIR/atea-pharmaceu...

all messages are opinion | Linktree do not assume accuracy no warranty is implied no liability of any kind exists

Bradley L. Radoff to Nominate Competing Slate and Engage with Atea Pharmaceuticals Board #AVIR

#microcap #stockholderdemocracy #activistinvestor

Disclaimer

linktr.ee/disclaimer462

Can Atea's 98% Effective HCV Drug Reshape the $3B Market? FDA Says Yes to Phase 3 Strong Phase 2 results with 98% cure rate drive FDA approval for Phase 3 trials. Company restructures operations while maintaining $454.7M cash position.

#AVIR Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/AVIR/atea-pharmaceu...

Atea Pharmaceuticals Targets $3B HCV Market with Phase 3 Trial Launch, Backed by $454M Cash Atea plans global Phase 3 trials for its HCV treatment in Q1 2025, featuring 8-week treatment regimen. Strong $454.7M cash position extends operations through 2028.

#AVIR Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/AVIR/atea-pharmaceu...

Atea Pharmaceuticals Faces Shareholder Revolt Over Director's Stock Sale, Strategic Decisions Major shareholders challenge leadership after director sells shares below cash value, demand resignation amid criticism of rejected $5.75/share acquisition offer.

#AVIR Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

www.stocktitan.net/news/AVIR/concerned-shar...

NEWS: ( NASDAQ: #AVIR ) Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

#StockMarket #News

Atea Pharmaceuticals Taps Evercore to Explore Strategic Options for Phase 3 HCV Program Atea partners with investment bank Evercore to evaluate strategic opportunities, focusing on potential partnerships for its Phase 3-ready hepatitis C treatment program.

#AVIR Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

www.stocktitan.net/news/AVIR/atea-pharmaceu...

#AVIR Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

www.stocktitan.net/news/AVIR/atea-pharmaceu...